When was Nanobiotix founded?

Nanobiotix was founded in 2003 and raised its 1st funding round 7 years after it was founded.

Where is Nanobiotix located?

Nanobiotix is headquartered in Paris, France.

How many employees does Nanobiotix have?

As of Apr 30, 2026, the latest employee count at Nanobiotix is 145.

Is Nanobiotix a funded company?

Nanobiotix is a funded company, having raised a total of $11M across 9 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on May 03, 2010.

When was the latest funding round of Nanobiotix?

Nanobiotix's latest funding was a $***** Post IPO round on Dec 04, 2023, with participation from 1 investor.

Where does Nanobiotix rank among its competitors?

Nanobiotix ranks 19th amongst 269 active competitors, of which 111 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was BridGene Biosciences, which secured $28M in Oct, 2025.

Who are the top competitors of Nanobiotix?

Nanobiotix's top competitors include Agios Pharmaceuticals, Hummingbird Bioscience and Lyell Immunopharma. Among them, BridGene Biosciences secured the most recent funding round in October, 2025.

Nanobiotix - 2026 Company Profile, Team, Funding & Competitors

Nanobiotix is a public company based in Paris (France), founded in 2003. It operates as a Developer of nanotherapeutics designed to enhance cancer treatment via radioenhancement. Nanobiotix has raised $11M in funding. The company has 269 active competitors, including 111 funded and 59 that have exited. Its top competitors include companies like Agios Pharmaceuticals, Hummingbird Bioscience and Lyell Immunopharma.

Company Details

Developer of nanotherapeutics designed to enhance cancer treatment via radioenhancement. Its lead candidate is designed to increase the dose of radiotherapy absorbed by tumor cells. This is intended to destroy the target tumor and prime the immune response. The company collaborates with institutions to develop therapies for cancer.

Website: nanobiotix.com
Social
Email ID: *****@nanobiotix.com
Phone Number: +33 **********

Key Metrics

Founded Year

2003

Location

Paris, France

Stage

Public

Total Funding

$11M in 9 rounds

Latest Funding Round

Post IPO, Dec 04, 2023, $*****

Investors

Masseran Gestion & 11 more

Ranked

19^th among 269 active competitors

Employee Count

145 as on Apr 30, 2026

Similar Companies

Agios Pharmaceuticals & 356 more

Exit Details

Public

View Nanobiotix's full profile

Nanobiotix got listed on Oct 29, 2012.

Click here to take a look at Nanobiotix's IPO in detail

Nanobiotix has raised a total funding of $11M over 9 rounds. Its first funding round was on May 03, 2010. Its latest funding round was a Post IPO round on Dec 04, 2023 for $*****. 1 investor participated in its latest round. Nanobiotix has 12 institutional investors.

Here is the list of recent funding rounds of Nanobiotix:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 04, 2023	7009553	Post IPO	6028908	7923755	6257800	9884213
Mar 04, 2019	4214010	Conventional Debt	6765018	4892249	2474559	European Investment Bank
Oct 16, 2018	4371574	Conventional Debt	9313195	7973068	9423587	European Investment Bank

Access funding benchmarks and valuations. Sign up today!

View details of Nanobiotix's funding rounds and investors

Nanobiotix's employee count trend

Nanobiotix has 145 employees as of Apr 26. Here is Nanobiotix's employee count trend over the years:

Uncover Nanobiotix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Nanobiotix include Agios Pharmaceuticals, Hummingbird Bioscience and Lyell Immunopharma. Here is the list of Top 10 competitors of Nanobiotix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Third Rock Ventures, Flagship Pioneering & 6 others	70/100
2nd	Hummingbird Bioscience 2015, Singapore (Singapore), Series C	Developer of antibody drugs for cancer treatment	$150M	OCTAVE Capital, GNTech Venture Capital & 23 others	68/100
3rd	Lyell Immunopharma 2018, San Francisco (United States), Public	Developer of CAR- T therapy for cancer treatment	$493M	Sahsen Ventures, GSK & 5 others	66/100
4th	Beijing Jiakesi drug development 2015, Beijing (China), Public	Developer of small molecule based therapeutics for cancer treatment	$55M	Qiming Venture Partners, Lilly Asia Ventures ... & 3 others	65/100
5th	Boundless Bio 2018, San Diego (United States), Public	Developer of therapeutics for cancer by targeting ecDNA	$252M	RA Capital Management, Bayer & 19 others	65/100
6th	ABL Bio 2016, Seongnam-si (South Korea), Public	Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases	$65M	QUAD, Hana Financial Group & 7 others	64/100
7th	Fusion Pharmaceuticals 2014, Hamilton (Canada), Acquired	Developer of targeted alpha therapeutics for the treatment of cancers	$171M	Varian Medical Systems, Seroba Life Sciences ... & 16 others	62/100
8th	Accent Therapeutics 2017, Lexington (United States), Series C	Developing RNA-modifying protein therapeutics for cancer with significant unmet medical need	$178M	EcoR1, The Column Group & 10 others	62/100
9th	Bolt Biotherapeutics 2015, Redwood City (United States), Public	Developer of T-cell therapies for the treatment of cancer	$177M	Pivotal bioVenture Partners, Sofinnova Investments ... & 7 others	61/100
10th	BridGene Biosciences 2018, Sunnyvale (United States), Series B	Developer of small-molecule drugs for the treatment of cancer	$78.5M	Deyi Capital, Kaitai Capital Management & 7 others	60/100
19th	Nanobiotix 2003, Paris (France), Public	Developer of nanotherapeutics designed to enhance cancer treatment via radioenhancement	$11M	Masseran Gestion, OTC Agregator & 10 others	60/100